ERBB2 and neoplasm: To our best knowledge, this is the first study investigating plasma HER2ECD or any other blood marker, including circulating tumor cells (CTCs) or free DNA, to address specifically the optimal time point for the introduction of chemotherapy after anti-HER2 monotherapy in HER2+ metastatic BC.